Tagged with B

Opinion Despite the savings and increased patient access biosimilars have brought to health care systems across Europe, the US has been surprisingly slow in their adoption. Chip Davis, President and CEO, Association for Accessible Medicines breaks down the systematic challenges that must be addressed in order for the US biosimilars market to realize…

South Korea This week the Korean Ministry of Food and Drug Safety announced that as of 12th March 2019 a revised narcotics bill will go into effect that will allow imports of medical cannabis for self-treatment but under strict conditions.   Until now, the import, export, manufacturing and sale of cannabis has been…

China One of the earliest innovative biotech companies in China, Zensun has developed what its founder Dr Zhou Mingdong calls a rare made-in-China first-in-class therapeutic candidate, the cardiology treatment, Neucardin®. With regulatory approval in the bag, Zensun is now expanding its new drug development to therapeutics for ageing-related diseases associated with…

France Dr Marc-Alexander Burmeister, president of B. Braun in France, shares the exciting changes to come for B. Braun globally and in France, and discusses the shifting environment of healthcare in the country for medtech players following the launch of the “My Health 2022” initiative by French Minister of Health &…

Opinion Brian Hilberdink, President of Novo Nordisk Canada, calls for the Canadian government to encourage and invest in innovative biopharmaceutical companies in Canada.    I’ve often wondered how things would be if Canada had steadily continued a path of biopharmaceutical discovery and commercialization after Banting and Best’s breakthrough in 1921, and what…

China This is the first in a series of articles examining what it takes to be a country manager of a multinational pharma company in some of the world’s most challenging markets. We start in China, where the heads of Merck, Ipsen, Chiesi, Gedeon Richter and AbbVie’s Chinese affiliates give their…

GW Pharma Founded in 1998, GW Pharmaceuticals is a British biopharmaceutical company, best known for being the only company with a license to cultivate cannabis in the UK. True pioneers, they are the producers of Sativex and Epiodiolex, the former being the world’s first prescription medicine derived from the cannabis plant —…

France Abbvie France’s Pierre-Claude Fumoleau outlines his strategic priorities for the affiliate, AbbVie’s unique corporate culture and ethos, and how he envisions upcoming regulatory reforms playing out in France.   We are still a very young company… and that means that we are still very much in the process of constructing…

Egypt Hassan Behnam, managing director of the French Chamber of Commerce and Industry in Egypt explains the investment opportunities Egypt has to offer, examines the close relationship between Egypt and France and highlights the recent visit of French President Emmanuel Macron to Egypt.   We at the French Chamber firmly believe…

Korea YJ Kim, country manager at BD Korea, discusses the integration of Bard into BD at the local level. He also offers his insights into the challenges of approval and pricing for medical devices and reveals BD’s future strategy to meet the demands of Korea’s ageing population.   The goal is…

France Denis Delval, CEO of iconic French pharma firm LFB since December 2017, discusses his key priorities to build the new LFB.   My vision is that we should be strong enough to assume a leadership position in any space that we seek to participate in During his two terms at…

Korea ISU Abxis, a subsidiary of the ISU conglomerate, is a biotech company with a focus on orphan drugs and rare disease. CEO Seok Joo Lee explains the rationale behind his decision to transform ISU Abxis’ international strategy from targeting developing markets to aiming for developed Western markets, such as the…